Health Care Resource Use and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Polypharmacy Patients With Obesity
Among patients with NVAF, polypharmacy, and obesity, rivaroxaban was associated with a reduction in HRU and all-cause costs compared with warfarin.
Authors
- Mark J. Alberts (ORCID: https://orcid.org/0000-0001-5488-6810)
- Akshay Kharat (ORCID: https://orcid.org/0000-0002-1056-9466)
- Christopher D. Pericone (ORCID: https://orcid.org/0000-0003-1394-6375)
- Veronica Ashton (ORCID: https://orcid.org/0000-0003-4880-1897)
- Jinghua He (ORCID: https://orcid.org/0000-0002-2058-5718)
Institutions
- Hartford Hospital (US)
- Johnson & Johnson (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1161/jaha.124.036401
- Citations
- 2
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Janssen Scientific Affairs